Warner-Lambert/Pfizer Lipitor overseas manufacturing illustrates shift from U.S. production sites.
PFIZER/WARNER-LAMBERT LIPITOR MANUFACTURING ILLUSTRATES DE-AMERICANIZATION of pharmaceutical manufacturing, Pfizer VP- Manufacturing Strategy Thomas Kline said Nov. 13 at IBC's PharmWorld '97 conference in Miami. The active ingredient for the HMG-CoA reductase inhibitor Lipitor (atorvastatin) is made by Warner-Lambert in Ireland, "the tablets are made by Warner-Lambert in Germany, the packaging for the U.S. market is done in Germany, the packaging for the rest of the world is done in Germany either by Warner-Lambert or Pfizer," Kline said.
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”
The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.
Experts from EUCOPE explain why the Council of the EU’s position on the proposed overhaul of the general pharmaceutical legislation could offer more predictability for companies than the commission’s initial offering.